Perspective Therapeutics, Inc.
CATX
$2.99
-$0.13-4.17%
AMEX
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -66.88% | -57.99% | -39.20% | -30.96% | -15.64% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -66.88% | -57.99% | -39.20% | -30.96% | -15.64% |
| Cost of Revenue | 72.17% | 88.08% | 102.26% | 84.05% | 96.76% |
| Gross Profit | -75.31% | -92.65% | -107.37% | -89.43% | -102.87% |
| SG&A Expenses | -4.26% | 2.80% | 13.60% | 35.27% | 47.90% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 45.02% | 56.47% | 67.69% | 61.78% | 72.65% |
| Operating Income | -46.64% | -58.70% | -70.01% | -64.28% | -75.30% |
| Income Before Tax | -20.36% | -29.57% | -29.84% | -117.68% | -120.46% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -22.17% | -31.84% | -32.31% | -84.40% | -83.23% |
| Earnings from Discontinued Operations | -61.67% | 204.90% | 154.16% | 108.38% | 107.43% |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -22.62% | -30.48% | -30.07% | -65.87% | -60.89% |
| EBIT | -46.64% | -58.70% | -70.01% | -64.28% | -75.30% |
| EBITDA | -46.78% | -59.53% | -71.04% | -64.42% | -74.67% |
| EPS Basic | 2.13% | -12.25% | -12.40% | 1.54% | 18.78% |
| Normalized Basic EPS | -31.05% | -57.90% | -59.92% | -11.79% | 12.06% |
| EPS Diluted | 2.13% | -12.25% | -12.40% | 1.54% | 18.78% |
| Normalized Diluted EPS | -31.05% | -57.90% | -59.92% | -11.79% | 12.06% |
| Average Basic Shares Outstanding | 32.40% | 19.13% | 17.52% | 32.78% | 63.46% |
| Average Diluted Shares Outstanding | 32.40% | 19.13% | 17.52% | 32.78% | 63.46% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |